Kandel M, Dalle S, Bardet A, et al. - Researchers used quality of life (QoL) data gathered via MelBase, which represents a prospective, French, multicentric cohort devoted to the follow-up of adults with metastatic melanoma (MM), to analyze QoL of patients suffering from MM in France, from their diagnosis of advanced disease to their death, in real life. The evaluation of QoL was done in 1,435 patients. A median follow-up of 9.4 months revealed the deaths of 47% of patients. During first-line therapy, the model-based, mean utility score, mean Functional Assessment of Cancer Treatment (FACT)-General score, and the mean FACT-Melanoma score were 0.830, 77.22, and 129.46, respectively. At the time of a change in treatment line, a reduction of −0.027, −1.82, and −2.98 was evident in the utility score, the FACT-General score, and in the FACT-Melanoma score, respectively, vs first-line treatment. Over the entire disease course, QoL appeared to be fairly stable among patients with MM in the MelBase cohort, although there was a small but significant reduction at time therapy was changed.